Saliva swab may predict liver risk in leukemia patients

NCT ID NCT03568266

Recruiting now Knowledge-focused Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects saliva samples from 500 people with newly diagnosed acute lymphoblastic leukemia to look for genetic markers linked to liver damage from the drug asparaginase. The goal is to better understand why some patients develop liver problems during treatment. No new drugs are being tested; the study simply observes and analyzes genetic information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which patients are at risk for liver damage from asparaginase, allowing for safer, personalized treatment plans.
What could go wrong: This is an early-stage pilot study focused on observation, not treatment. It may not find clear genetic markers, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Los Angeles General Medical Center
RECRUITING

Los Angeles, California, 90033, United States
USC / Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.